Evotec SE (EVO) Análisis de acciones

Descripción de la empresa

Evotec SE operates as a specialized drug discovery and development company with a significant international footprint, maintaining active operations in the United States, Germany, France, the United Kingdom, Switzerland, and other global markets. The enterprise functions within the Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which distinguishes it from large-scale pharma giants by focusing on specialized manufacturing and research services. As of the latest data, the company commands a market capitalization of $924.28M while generating annual revenues of $756.33M and employing a workforce of 4788 individuals. These financial dimensions indicate that Evotec maintains a substantial operational scale within the specialty pharmaceutical space, yet its market cap suggests a valuation that does not reflect a dominant monopoly position but rather a mid-tier player subject to the volatility of R&D-dependent businesses.

Salud financiera

The company reported a revenue of $756.33M over the trailing twelve months, yet this top-line figure masks a significant operational challenge as the net income stands at $-158,980,000 and EBITDA is merely $13,000. The substantial disparity between the $756.33M in revenue and the negative net income reveals a cost structure characterized by high operating expenses that completely absorb gross profitability, resulting in a lack of bottom-line retention. Free cash flow stands at $-207,618,880, indicating that the company is burning cash at a rapid pace, which severely constrains its financial flexibility and necessitates external capital injections to sustain operations. Profitability metrics are deeply concerning, with a gross margin of 10.8%, an operating margin of -26.6%, and a profit margin of -21.0%, suggesting that the company struggles to convert sales into efficient profits across all levels of its financial statement. The balance sheet presents a leveraged profile with total debt of $484.62M against cash holdings of $237.27M, resulting in a debt-to-equity ratio of 60.57, which implies that the company relies heavily on debt financing relative to its equity base. Liquidity is supported by a current ratio of 2.12, which indicates that the company possesses more than double the current assets needed to cover its short-term liabilities, providing a buffer despite the cash burn. Furthermore, the return metrics show a return on equity of -18.0% and a return on assets of -2.7%, revealing that management is currently generating negative returns on both shareholder capital and the asset base, signaling an inability to effectively deploy resources to generate value in the current fiscal cycle.

Evaluación de valoración

Valuation metrics present a complex picture due to the absence of positive earnings, with the trailing P/E ratio listed as N/A and a forward P/E of -13.58, which implies that the market is pricing in a significant turnaround or restructuring to achieve positive earnings in the future. The price-to-book ratio is 0.99, indicating that the market values the company at nearly its book value, which suggests no significant market premium is being applied despite the specialized nature of its drug discovery services. Alternative valuation measures such as the price-to-sales ratio of 1.22 and an EV/EBITDA of 54287.57 highlight the difficulty in applying traditional multiples, where the EV/EBITDA figure is artificially inflated due to negligible EBITDA relative to enterprise value. Price momentum shows a 52-week high of $4.80 and a 52-week low of $2.31, meaning the stock is currently trading within this range, reflecting high sensitivity to sector-specific news and R&D pipeline updates. The beta of 1.24 indicates that the stock exhibits volatility that is 24% higher than the broader market, making it a riskier investment proposition compared to low-beta healthcare peers.

Growth & Income

Revenue growth year-over-year is -11.4%, while earnings growth is N/A due to the negative net income, meaning the company is contracting rather than expanding its top line and has no earnings trajectory to analyze. As the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that all available cash flow is being retained and reinvested into the business rather than distributed to shareholders. The absence of a dividend payout ratio eliminates concerns regarding sustainability, as the firm prioritizes capital allocation toward research and development activities essential for its drug discovery model. Overall, the growth and income profile is defined by revenue contraction and negative earnings, reflecting a phase of intense investment where income generation is secondary to maintaining a viable pipeline and operational continuity.